Fig. 2: Long intergenic non-protein coding RNA 1291 (LINC01291) decreases miR-625-5p expression in melanoma cells by serving as a miR-625-5p sponge. | Cancer Gene Therapy

Fig. 2: Long intergenic non-protein coding RNA 1291 (LINC01291) decreases miR-625-5p expression in melanoma cells by serving as a miR-625-5p sponge.

From: Long noncoding RNA LINC01291 promotes the aggressive properties of melanoma by functioning as a competing endogenous RNA for microRNA-625-5p and subsequently increasing IGF-1R expression

Fig. 2

A lncLocator predicted the localization of LINC01291. B Subcellular fractionation assay revealed that LINC01291 was mostly distributed in the cytoplasm of A-375 and HT-144 cells. C A total of nine miRNAs were identified via bioinformatics analysis to contain binding sequences for LINC01291. D, E Expression of miR-625-5p and miR-766-5p in melanoma, as analyzed using The Cancer Genome Atlas (TCGA) database. **P < 0.01 vs. group “Normal”. F Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure miR-625-5p and miR-766-5p expression in A-375 and HT-144 cells after LINC01291 interference. **P < 0.01 vs. group “si-NC”. G Total RNA was extracted from 41 pairs of human melanoma tissues and corresponding adjacent normal tissues and subjected to qRT-PCR for miR-625-5p quantification. **P < 0.01 vs. group “Normal”. H Pearson correlation analysis was used to analyze the association between miR-625-5p and LINC01291 expression in the 41 melanoma tissues. I Radioimmunoprecipitation (RIP) assay was performed to test the binding interaction between LINC01291 and miR-625-5p in melanoma cells. **P < 0.01 vs. group “IgG”. J The predicted binding sequences of miR-625-5p within LINC01291 and target-site mutation. K A-375 and HT-144 cells were transfected with miR-625-5p or negative control (NC) mimic along with LINC01291-WT or LINC01291-MUT. Luciferase activity was detected at 48 h after transfection. **P < 0.01 vs. group “NC mimic”.

Back to article page